| Prev Close | 87.76 |
| Day Low/High | 87.45 / 88.33 |
| 52 Wk Low/High | 62.87 / 87.84 |
| Avg Volume | 5.11M |
Abbott Laboratories (ABT)
87.49
NYSE : Health Technology
| Exchange | NYSE |
| Shares Outstanding | 1.76B |
| Market Cap | 154.82B |
| EPS | 1.30 |
| P/E Ratio | 59.70 |
| Div & Yield | 1.28 (1.40%) |
Latest News
Jim Cramer: These 7 True Laggards Have Caught Fire
These kinds of stocks are what goes up when there's so little left that hasn't moved that can still be worth buying.
Good News From China, Plus Netflix Earnings and Playing CSX: Market Recon
China reported positive data, bolstering markets. Netflix had a beat on earnings, but faces fierce competition ahead. CSX is a thing of beauty.
Trading Notes for Select Stocks
Here's my take on a list of stocks I've been watching.
Shares of Abbott Laboratories Poised for Upside Breakout
ABT is pointed up after trading in a choppy range since October.
An IBM Play and 2 Catalysts To Watch in Wednesday's Trading: Market Recon
Keeping an eye on the Senate shutdown vote and any trade discussion today, and watching key support levels on the SPX.
Jim Cramer: If We Get a China Deal, Then This Rally Is In Its Infancy
The kick will come from the Chinese capitulating because their economy is so weak.
New Favorites for 2019 from Last Year's Top Stock Pickers
Mike Cintolo and Jim Woods saw their top picks for 2018 rise 81% and 75%, respectively.
This 2019 Market Optimism Is Misplaced: Market Recon
Take upbeat outlooks for equities with a grain of salt, and try these sectors to stay safe.
Pfizer, Other Pharma Stocks Should Continue to Do Well Amid Market Volatility
Pfizer trades with a trailing PE of 15 and is expected to grow earnings 2% in 2019.
Here Are 9 Takeaways From Last Night's Meltdown: Market Recon
It becomes difficult for me to tell you where to run in these markets...
Why Netflix Is a Good Name to Short on This Earnings Report: Market Recon
I am unimpressed by the latest earnings report. Despite good subscriber growth, fundamentals look weak.
Sell Abbott Laboratories Down to a 'Sleeping Position'
While Abbott's charts are not screaming sells, there are enough signals to suggest a cautious approach to earnings.
Jim Cramer: Know Which Way the Wind Blows Before You Pick Stocks
PepsiCo, GE and just like the weather, the stock market is subject to change.
Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter
Straying from these names could land you in quicksand as the 4th quarter begins.
Jim Cramer: Valuations Now Have No Relation to Common Sense
Analyst downgrades and mind-boggling P/E ratios do not matter in this current market.
Jim Cramer: 5 Sectors to Buy on This 'Turkish Contagion' Market Drop
It is all about perception, and here are strong names to pick up on market weakness.
Sector Rotation Is Powerful: This Tech Hit Is a Great Trade
As hedge funds are forced to unwind tech positions, here is how to play the rotation.
Pullback in Abbott Labs Gives Buyers Another Chance
Our latest analysis and strategy on ABT shares.
Jim Cramer: Trade Wars and Tariffs May Soon Be Baked Into Pricing
Earnings have been strong, and analysts will soon start to concentrate more on actual weakness than shadow-boxing weakness.
Abbott Laboratories Gaps to the Upside in a Classic Breakout
If you are long ABT continue to hold and raise sell stop protection to a close below $59 or where the 200-day moving average line intersects.
Here Are 6 Chip Stocks That I Like Better Than Texas Instruments: Market Recon
This group is expected to post second-quarter EPS gains of 30%; here is how to trade it.
Medical Device Stocks Could Be Gearing Up to Be Market Leaders
When chartists look for the next market leaders they often go to stocks that have held up the best during corrections.
Jim Cramer: When Rates Decline, 96% of the S&P 500 Benefits
When rates decline, most of the S&P 500 benefits, according to TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer.
Jim Cramer: Stocks That Do Well In a Declining Rate Environment Are Back
The crash of oil will only accelerate the move.
Why I'm Not Piling 'All In' to the Banks: Market Recon
Market reactions have ranged anywhere from lackluster to outright negative. What gives?
Jim Cramer: We've Got a Battle Ahead of Us, But the Fed Might Resolve It
Sectors are saying different things about rates, but new Fed chief Jerome Powell could provide clarity at his first press conference on Wednesday.
